Neuroblastoma remains the leading cause of cancer deaths in children under five, highlighting the urgent need for innovative therapies. CAR-T cell therapies for this indication face several obstacles such as limited persistence and efficacy of CAR-T cells. Therefore, there is a high need for optimized neuroblastoma-specific CAR-T cell therapies. Annette Künkele-Langer and her team aim to develop novel CAR constructs to generate CAR-T cells for neuroblastoma therapy and subject these cells to a detailed preclinical validation. The ultimate aim is the development of a successful cell therapy for this deadly childhood cancer which would represent a milestone in the history of pediatric oncology.